Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

NCT01397201 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Placebo
DRUG: BI 54903
DRUG: Fluticasone propionate

Sponsor

Boehringer Ingelheim